WO2005113600A3 - Methodes de regulation, de traitement et de prise en charge de l'obesite - Google Patents

Methodes de regulation, de traitement et de prise en charge de l'obesite Download PDF

Info

Publication number
WO2005113600A3
WO2005113600A3 PCT/GB2005/001916 GB2005001916W WO2005113600A3 WO 2005113600 A3 WO2005113600 A3 WO 2005113600A3 GB 2005001916 W GB2005001916 W GB 2005001916W WO 2005113600 A3 WO2005113600 A3 WO 2005113600A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
receptors
control
signalling molecules
signal
Prior art date
Application number
PCT/GB2005/001916
Other languages
English (en)
Other versions
WO2005113600A2 (fr
Inventor
Keith Charlton
Andrew Porter
Gillian Strachan
Original Assignee
Haptogen Ltd
Keith Charlton
Andrew Porter
Gillian Strachan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd, Keith Charlton, Andrew Porter, Gillian Strachan filed Critical Haptogen Ltd
Publication of WO2005113600A2 publication Critical patent/WO2005113600A2/fr
Publication of WO2005113600A3 publication Critical patent/WO2005113600A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des méthodes de régulation des troubles du système nerveux central par le biais de la modulation de la concentration extracellulaire de molécules de signalisation de cellules hormonales de peptide et de cannabinoïdes endogènes. Des dérivés de molécules de signalisation cellulaire sont conjugués à des protéines porteurs appropriées et utilisés pour isoler des récepteurs à haute affinité reconnaissant les molécules signal endogènes parmi les bibliothèques de récepteurs appropriés. Du fait de leur liaison aux molécules de signalisation, les récepteurs réduisent les concentrations disponibles de molécules signal et modulent les réponses physiologiques commandées par ces dernières. De plus, les conjugués selon l'invention peuvent être utilisés en tant que vaccins pour stimuler chez des patients les réponses immunes de molécule anti-signal.
PCT/GB2005/001916 2004-05-18 2005-05-18 Methodes de regulation, de traitement et de prise en charge de l'obesite WO2005113600A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0411014A GB0411014D0 (en) 2004-05-18 2004-05-18 Methods for the control treatment and management of obesity
GB0411014.4 2004-05-18

Publications (2)

Publication Number Publication Date
WO2005113600A2 WO2005113600A2 (fr) 2005-12-01
WO2005113600A3 true WO2005113600A3 (fr) 2006-06-08

Family

ID=32607479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/001916 WO2005113600A2 (fr) 2004-05-18 2005-05-18 Methodes de regulation, de traitement et de prise en charge de l'obesite

Country Status (2)

Country Link
GB (1) GB0411014D0 (fr)
WO (1) WO2005113600A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
KR101481036B1 (ko) 2008-05-15 2015-01-09 (주)아모레퍼시픽 아라키도닐 도파민을 함유하는 지방세포 분화 억제 및지방세포 내의 지질체 수준 감소용 약학 조성물
WO2013014269A1 (fr) 2011-07-28 2013-01-31 Intervet International B.V. Procédé pour la promotion de la croissance d'un animal nouveau-né

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087335A2 (fr) * 2000-05-17 2001-11-22 Eli Lilly And Company Procede d'inhibition selective de la ghreline
WO2003026591A2 (fr) * 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Modification de comportement alimentaire
WO2004009124A2 (fr) * 2002-07-19 2004-01-29 Cytos Biotechnology Ag Conjugues de porteurs de ghrelin
WO2004024183A1 (fr) * 2002-09-12 2004-03-25 Pharmexa A/S Immunisation contre la ghreline autologue
WO2005016951A2 (fr) * 2003-06-04 2005-02-24 Eli Lilly And Company Anticorps contre la ghreline
WO2005026211A2 (fr) * 2003-09-05 2005-03-24 Eli Lilly And Company Anticorps anti-ghreline

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087335A2 (fr) * 2000-05-17 2001-11-22 Eli Lilly And Company Procede d'inhibition selective de la ghreline
WO2003026591A2 (fr) * 2001-09-24 2003-04-03 Imperial College Innovations Ltd. Modification de comportement alimentaire
WO2004009124A2 (fr) * 2002-07-19 2004-01-29 Cytos Biotechnology Ag Conjugues de porteurs de ghrelin
WO2004024183A1 (fr) * 2002-09-12 2004-03-25 Pharmexa A/S Immunisation contre la ghreline autologue
WO2005016951A2 (fr) * 2003-06-04 2005-02-24 Eli Lilly And Company Anticorps contre la ghreline
WO2005026211A2 (fr) * 2003-09-05 2005-03-24 Eli Lilly And Company Anticorps anti-ghreline

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BASTA P V ET AL: "Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide", JOURNAL OF IMMUNOLOGICAL METHODS, ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM, NL, vol. 285, no. 2, 15 February 2004 (2004-02-15), pages 181 - 195, XP004491163, ISSN: 0022-1759 *
BATTERHAM R L ET AL: "Gut hormone PYY [3-36] physiologically inhibits food intake", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 418, 8 August 2002 (2002-08-08), pages 650 - 654, XP002984562, ISSN: 0028-0836 *
BATTERHAM R L ET AL: "INHIBITION OF FOOD INTAKE IN OBESE SUBJECTS BY PEPTIDE YY3-36", NEW ENGLAND JOURNAL OF MEDICINE, THE, MASSACHUSETTS MEDICAL SOCIETY, WALTHAM, MA, US, vol. 349, no. 10, 4 September 2003 (2003-09-04), pages 941 - 948, XP008054301, ISSN: 0028-4793 *
LIN H C ET AL: "FAT-INDUCED ILEAL BRAKE IN THE DOG DEPENDS ON PEPTIDE YY", GASTROENTEROLOGY, SAUNDERS, PHILADELPHIA, PA,, US, vol. 110, no. 5, 1 May 1996 (1996-05-01), pages 1491 - 1495, XP000613220, ISSN: 0016-5085 *
MARZO DI V ET AL: "LEPTIN-REGULATED ENDOCANNABINOIDS ARE INVOLVED IN MAINTAINING FOOD INTAKE", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 410, 12 April 2001 (2001-04-12), pages 822 - 825, XP000996642, ISSN: 0028-0836 *
MASAMITSU NAKAZATO ET AL: "A role for ghrelin in the central regulation of feeding", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 409, 11 January 2001 (2001-01-11), pages 194 - 198, XP002901678, ISSN: 0028-0836 *
MURAKAMI N ET AL: "Role for central ghrelin in food intake and secretion profile of stomach ghrelin in rats", JOURNAL OF ENDOCRINOLOGY, BRISTOL, GB, vol. 174, no. 2, August 2002 (2002-08-01), pages 283 - 288, XP009022559, ISSN: 0022-0795 *
RAYBOULD HELEN E ET AL: "PYY immunoneutralization does not alter lipid-induced inhibition of gastric emptying in rats", REGULATORY PEPTIDES, vol. 79, no. 2-3, 5 February 1999 (1999-02-05), pages 125 - 130, XP002365655, ISSN: 0167-0115 *
TSCHOP M ET AL: "GHRELIN INDUCES ADIPOSITY IN RODENTS", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 407, 19 October 2000 (2000-10-19), pages 908 - 913, XP002951587, ISSN: 0028-0836 *
YANG H ET AL: "PERIPHERAL PYY INHIBITS INTRACISTERNAL TRH-INDUCED GASTRIC ACID SECRETION BY ACTING IN THE BRAIN", AMERICAN JOURNAL OF PHYSIOLOGY, AMERICAN PHYSIOLOGICAL SOCIETY, BETHESDA, MD, US, vol. 279, no. 3, PART 1OF02, September 2000 (2000-09-01), pages G575 - G581, XP001061487, ISSN: 0002-9513 *
ZHAO XIAO-TUAN ET AL: "Intestinal fat-induced inhibition of meal-stimulated gastric acid secretion depends on CCK but not peptide YY", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 276, no. 2 PART 2, February 1999 (1999-02-01), pages G550 - G555, XP002365654, ISSN: 0002-9513, Retrieved from the Internet <URL:http://www.ajpgi.physiology.org> [retrieved on 20060131] *

Also Published As

Publication number Publication date
WO2005113600A2 (fr) 2005-12-01
GB0411014D0 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
HUP0400284A2 (hu) Rekombináns, tumorspecifikus ellenanyag és alkalmazása
IS6455A (is) Stöðvun á vexti taugasíma fyrir milligöngu viðtaka Nogo
MY154826A (en) Fusion protein capable of binding vegf
EA200600869A1 (ru) Антитела, связывающие рецептор интерлейкина-4
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
DK0975754T3 (da) Osteoprotegerin bindende proteiner og receptorer
WO2005120557A3 (fr) Inhibition du recepteur proteique stimulant les macrophages (ron)
WO2004037999A3 (fr) Adn et proteines 3 de type a34 et a33, anticorps associes et methodes de traitement associees
WO2005035551A3 (fr) Inhibiteurs de proteines se liant a des molecules phosphorylees
WO2002029059A3 (fr) Homologues du recepteur de nogo
TW200635946A (en) Binding proteins specific for human matriptase
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
HK1084676A1 (en) Antibody anti human nogo a and its pharmaceutical use
WO2005113600A3 (fr) Methodes de regulation, de traitement et de prise en charge de l&#39;obesite
WO2005051902A3 (fr) Canal proteique mscl modifie
WO2005089445A3 (fr) Follicule stimulant les superagonistes d&#39;une hormone
WO2003068800A3 (fr) Peptides isoles qui se lient aux molecules hla et leurs utilisations
WO2002083856A3 (fr) Polynucleotides codant deux nouveaux recepteurs couples aux proteines g, hgprbmy28 et hgprbmy29, et leurs variants d&#39;epissage
WO2021212053A3 (fr) Anticorps anti-musk thérapeutiques
Krzyscik et al. Cyclic and dimeric fibroblast growth factor 2 variants with high biomedical potential
WO2002004491A3 (fr) Procedes et compositions relatifs a la proteine d&#39;interaction de calcineurine selective musculaire (mcip)
IL149045A0 (en) Diagnosis and therapy of cancer using sgp28-related molecules
EP1939217A3 (fr) Plasmides codant pour des variantes de séquence de la protéine p185neu et utilisations thérapeutiques correspondantes
MX2022005595A (es) Método para tratar o mejorar el síndrome de cushing usando proteínas de unión para el receptor peptídico inhibidor gástrico (gipr).
WO2006110367A3 (fr) Procedes et compositions pour toxines mycoplasma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase